Efficacy of Selpercatinib in RET -Altered Thyroid Cancers

J. Wirth, Lori; J. Sherman, Eric; Robinson, Bruce; Solomon, Benjamin; Kang, Hyunseok; H. Lorch, Jochen; P. Worden, Francis; S. Brose, Marcia; D. Patel, Jyoti; Leboulleux, Sophie; Godbert, Yann; Barlési, Fabrice; C. Morris, John; K. Owonikoko, Taofeek; S.W. Tan, Daniel; Gautschi, Oliver; Weiss, Jared; de la Fouchardière, Christelle; E. Burkard, Mark; Laskin, Janessa; H. Taylor, Matthew; Kroiß, Matthias; Médioni, Jacques; W. Goldman, Jonathan; M. Bauer, Todd; Levy, Benjamin; W. Zhu, Viola; J. Lakhani, Nehal; Moreno, Víctor; Ebata, Kevin; Nguyen, Michele; Heirich, Dana; Y. Zhu, Edward; Huang, Xin; Yang, Luxi; Kherani, Jennifer; Michael Rothenberg, S.; Drilon, Alexander; Subbiah, Vivek; H. Shah, Manisha; E. Cabanillas, Maria

doi:10.1056/nejmoa2005651

Public

Efficacy of Selpercatinib in RET -Altered Thyroid Cancers

Published in New England Journal of Medicine • Aug 26, 2020

Authors:

Lori J. Wirth

Eric J. Sherman

Bruce Robinson

Abstract

BACKGROUND: -altered thyroid cancers, the efficacy and safety of selective RET inhibition are unknown. METHODS: fusion-positive thyroid cancer, in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response), as determined by an independent rev...

Subject

Medicine

Thyroid

Proto-Oncogene Proteins c-ret

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!